Startseite » Forschung » Haarmultiplikation » update intercytex
christian77 ist gerade offline  christian77
update intercytex [Beitrag #135865] :: Do., 18 September 2008 09:23 Zum vorherigen Beitrag gehen
dachte ich mach nen neuen thread auf, weil der alte schon so zerfurcht ist...

http://www.intercytex.com/icx/news/releases/2008/2008-09-18/

Intercytex Group plc – Interim results for the six months ended 30 June 2008

18th September 2008

Intercytex Group plc (LSE: ICX), the regenerative medicine company developing innovative products to restore skin and hair, announces its interim results for the six months ended 30 June 2008.

PRODUCT HIGHLIGHTS

Cyzact® (ICX-PRO) - healing chronic wounds

* Phase III trial in venous leg ulcers fully recruited; data expected to be announced around the end of Q1/2009 with filing of the BLA in the second half of that year
* Final positive Phase II data from diabetic foot ulcer trial of Cyzact® presented at EWMA conference in Lisbon

VAVELTA® - natural repair for damaged skin

* First commercial sales of VAVELTA® commenced in June; rollout of distribution network underway with over 15 clinics now accredited
* Positive final data from two Phase II trials of VAVELTA® presented in June at FACE congress in London, UK
* Further positive responses being generated from field trials of VAVELTA® conducted by the Clinical Practice Group with around 50 patients treated by this group to date
* Treatment commenced in a third Phase II trial for burns scars (including contractures); trial extended to up to 30 patients with additional centres being enrolled

ICX-SKN - skin grafts for acute wounds

* Phase I study showed integration of graft in all 12 patients persisting for up to 6 months
* Product being reformulated for trauma and burns applications for US Phase II clinical trial as part of the AFIRM award

ICX-TRC - hair regeneration

* Data from the Phase II trial shows increase in hair count in 11 out of 14 (79%) evaluable subjects at 24 weeks

CORPORATE AND FINANCIAL HIGHLIGHTS

* Placing of new shares to existing shareholders completed on 8th September 2008 raising £2.75m gross
* Intercytex the only non-US participant in a group awarded substantial funding to establish US Armed Forces Institute of Regenerative Medicine (AFIRM); initial funding available to support development of ICX-SKN for burns in the US
* Awarded grant from the Technology Strategy Board of £285k over 3 years to assist with development of strategies for preservation and storage of cell therapy products
* Positive report received from Human Tissue Authority following inspection of our Manchester GMP facility
* Loss before tax for the six months ended 30 June 2008 of £6.59m (H1 2007: £6.04m)
* Cash and cash equivalents and liquid investments at 30 June 2008 of £6.36m (H1 2007: £17.55m)

[Aktualisiert am: Do., 18 September 2008 09:24]

Den Beitrag einem Moderator melden

 Eine private Nachricht an diesen Benutzer verschicken  
 
[Beitragsindex]
 
Gelesene Nachricht
Gelesene Nachricht
Gelesene Nachricht
Gelesene Nachricht
Gelesene Nachricht
Gelesene Nachricht
Gelesene Nachricht
Gelesene Nachricht
Gelesene Nachricht
Gelesene Nachricht
Gelesene Nachricht
Gelesene Nachricht
Gelesene Nachricht
Gelesene Nachricht
Gelesene Nachricht
Gelesene Nachricht
Gelesene Nachricht
Gelesene Nachricht
Gelesene Nachricht
Gelesene Nachricht
Gelesene Nachricht
Gelesene Nachricht
Gelesene Nachricht
Gelesene Nachricht
Gelesene Nachricht
Gelesene Nachricht
Gelesene Nachricht
Gelesene Nachricht
Gelesene Nachricht
Gelesene Nachricht
Gelesene Nachricht
Gelesene Nachricht
Gelesene Nachricht
Gelesene Nachricht
Gelesene Nachricht
Gelesene Nachricht
Gelesene Nachricht
Gelesene Nachricht
Gelesene Nachricht
Gelesene Nachricht
Gelesene Nachricht
Gelesene Nachricht
Gelesene Nachricht
Gelesene Nachricht
Gelesene Nachricht
Gelesene Nachricht
Gelesene Nachricht
Gelesene Nachricht
Gelesene Nachricht
Gelesene Nachricht
Gelesene Nachricht
Gelesene Nachricht
Gelesene Nachricht
Gelesene Nachricht
Gelesene Nachricht
Gelesene Nachricht
Gelesene Nachricht
Gelesene Nachricht
Gelesene Nachricht
Gelesene Nachricht
Gelesene Nachricht
Gelesene Nachricht
Gelesene Nachricht
Gelesene Nachricht
Gelesene Nachricht
Gelesene Nachricht
Gelesene Nachricht
Gelesene Nachricht
Gelesene Nachricht
Gelesene Nachricht
Gelesene Nachricht
Gelesene Nachricht
Gelesene Nachricht
Gelesene Nachricht
Gelesene Nachricht
Gelesene Nachricht
Gelesene Nachricht
Gelesene Nachricht
Gelesene Nachricht
Gelesene Nachricht
Gelesene Nachricht
Gelesene Nachricht
Gelesene Nachricht
Gelesene Nachricht
Gelesene Nachricht
Gelesene Nachricht
Gelesene Nachricht
Gelesene Nachricht
Gelesene Nachricht
Gelesene Nachricht
Gelesene Nachricht
Gelesene Nachricht
Gelesene Nachricht
Vorheriges Thema: "The Cure" 2010"!Wer ist alles dafür?
Nächstes Thema: Risiko Stammzellen / Haarmultiplikation
Gehe zum Forum:
  

[ Themen als Syndikate anderen Seiten zur Verfügung stellen (XML) ] [ RSS ] [ PDF ]

aktuelle Zeit: So. Jul 21 00:31:47 MESZ 2024

Insgesamt benötigte Zeit, um die Seite zu erzeugen: 0.01240 Sekunden
Letzte 10 Themen



Videos / Infos
Video Schuppen / seborrhoisches Ekzem


Partner Hairforlife FUE EUROPE
» Neurodermitis :: » ADS (ADHS) :: Impressum / Datenschutz
.:: Kontakt :: Forumsindex ::.

Betrieben mit: FUDforum 3.1.3.
Copyright ©2001-2023 FUDforum Bulletin Board Software